SAN DIEGO, Sept. 14, 2016 /PRNewswire/ -- Metacrine, Inc., a biotechnology company focused on developing innovative therapeutics in metabolic disease through advances in endocrine research, today announced the appointment of Ken Song, M.D., as its new president, chief executive officer and
Appoints Neil McDonnell, CEO, Along with Executive Team and Board San Diego, CA – Metacrine, Inc., a biotechnology company focused on targeting metabolic disease through advances in endocrine research, today announced it has raised $36 million in a Series A financing.